Inhibin is a disulphide-linked dimeric 32 kDa glycoprotein hormone composed of a and b subunits. The b subunit exists as at least four isoforms. Inhibin suppresses FSH secretion. Activin, which stimulates FSH secretion, is composed of two b subunits. It is therefore the presence of the a subunit which is specific for inhibin6.
Monoclonal antibodies appear to have an narrower range of immunoreactivity than polyclonal antibodies. Most published data is based on the monoclonal R1 antibody from Serotec, which is directed against the a subunit. E4 is directed against the bA subunit and therefore is immunoreactive with both activin and inhibin. Antibodies are effective on paraffin-embedded tissue6.
Normal tissues6:
stromal hyperthecosis (8/814)
ovarian sex cord stromal neoplasms. Inhibin is more specific but less sensitive than calretinin.
ovarian sex cord stromal tumours: |
|
granulosa cell tumour |
37/395, 42/437, 16/169, 6/610, 3/310, 6/611, 66/6612 , 5/613, 26/2614, 16/1616, 32/3318, 1/119, 33/3520, 28/2821, 14/1422 |
Sertoli-Leydig cell tumours |
12/135, 7/87, 1/19, 10/1118, 7/1121, 8/814, 3/322 |
4/45, 17/1712, 6/1121, 1/114 |
|
thecoma |
8/95, 16/1812, 10/1121 |
fibrothecoma |
11/145, 4/57, 10/109, 4/614, 10/1420 |
sclerosing stromal tumour |
2/25, 0/212, 2/214, 4/1121 |
steroid cell |
3/35, 6/612, 2/214, 8/921 |
other stromal neoplasms |
3/35 |
primitive gonadal stromal tumour |
5/67, 2/314 |
gonadoblastoma |
3/314, 2/521 |
gynandroblastoma |
1/114, 1/115, 1/121 |
sex cord tumour with annular tubules |
2/214, 12/1221, 1/122 |
lipid cell tumour |
6/77, 1/19 |
sex cord stromal tumours, NOS |
17/1820, 1/221 |
sex cord-stromal tumours, overall |
80/875, 50/508 |
other primary ovarian tumours: |
|
fibroma |
17/205, 0/1212, 3/1121, 2/321 |
adenofibroma |
0/95 |
fibrosarcoma |
5/85, 0/1021 |
serous carcinoma |
1/115, 1/28, 0/726 |
atypical mucinous neoplasm / mucinous adenocarcinoma |
0/195, 0/526 |
primary ovarian clear cell carcinoma |
0/75, 2/28, 1/116 |
endometrioid carcinoma |
|
sertoliform endometrioid carcinoma |
0/87 |
epithelial tumours, NOS |
|
Brenner tumour |
0/135, 1/920 |
9/1021 |
|
malignant mixed Müllerian tumour |
0/25, 0/1212 |
dysgerminoma |
0/75, 0/618 |
yolk sac tumour |
0/55 |
choriocarcinoma |
0/15 |
embryonal carcinoma |
0/15 |
immature teratoma |
0/45 |
mixed germ cell tumour |
0/45, 0/612, 1/2421 |
ovarian small cell carcinoma |
|
extrauterine endometrial stromal sarcomas |
0/57, 0/214 |
clear cell sarcoma |
0/15 |
haemangiopericytoma |
0/15 |
myxoma |
0/312 |
carcinoid |
0/518, 0/314 |
lymphoma |
0/17, 0/212, 0/318, 0/514 |
struma ovarii |
0/114 |
tumours metastatic to ovary: |
|
metastatic carcinoma to ovary |
0/1514 |
metastatic uterine clear cell carcinoma |
1/38 |
metastatic melanoma |
0/17 |
metastatic carcinoid to ovary |
0/214 |
endometrial stromal sarcoma metastatic from uterus |
0/214 |
testicular tumours: |
|
Leydig cell tumour |
15/1617 |
testicular sex cord-stromal tumors with varying degrees of Sertoli or granulosa cell differentiation |
4/617 |
sex cord-stromal tumors, NOS |
2/317 |
|
|
uterine endometrioid carcinoma |
1/28, 3/526 |
thyroid carcinoma |
1/426 |
colonic adenocarcinoma |
9/1226 |
gallbladder adenocarcinoma |
0/526 |
pancreatic adenocarcinoma |
0/326 |
breast carcinoma |
1/88, 4/926 |
lung adenocarcinoma |
2/526 |
gastric adenocarcinoma |
0/726 |
renal cell carcinoma |
1/526 |
prostatic adenocarcinoma |
0/726 |
bladder adenocarcinoma |
0/226 |
transitional cell carcinoma |
1/38 |
haemangiopericytoma |
0/310 |
malignant melanoma |
1/58 |
extra-ovarian stromal tumours |
|
19/2028 |
|
0/3227 |
|
0/2827 |
|
1/1527 |
|
uterine undifferentiated sarcoma |
0/427 |
Uterine tumours with sex cord differentiation(1/23, 3/74).
Testicular Leydig cell tumours and Sertoli cell tumours.
Trophoblast and decidua:
trophoblast |
decidua |
|
intrauterine products of conception |
36/3625 |
5/40 |
extrauterine products of conception |
4/425 |
1/425 |
decidualised endometrium in context of ectopic gestation |
|
2/725 |
decidualised endometrium in context of progesterone therapy |
|
2/825 |
Extrauterine decidualised tissue in context of intrauterine pregnancy |
|
1/325 |
hydatidiform mole |
5/525 |
|
uterine choriocarcinoma |
2/225 |
|
testicular embryonal carcinoma with syncytiotrophoblastic giant cells |
6/625 |
|
Inhibin immunoreactivity has been reported in hepatocellular carcinoma and as possibly useful in the differentiation of hepatocellular carcinomas (positive) from adenocarcinomas (negative)1. However, a subsequent publication indicates that the reported immunopositivity of HCC and non-tumoral hepatocytes for inhibin represents a false-positive result due to endogenous biotin2.
serous adenocarcinoma of ovary |
4/726 |
|
mucinous adenocarcinoma of ovary |
2/526 |
|
endometrioid adenocarcinoma of ovary |
1/226 |
|
endometrial adenocarcinoma |
5/526 |
|
colonic adenocarcinoma |
10/1226 |
|
5/526 |
||
breast carcinoma |
7/926 |
|
gastric adenocarcinoma |
2/726 |
|
prostatic adenocarcinoma |
3/726 |
|
bladder adenocarcinoma |
0/226 |
|
gallbladder adenocarcinoma |
1/526 |
|
renal cell carcinoma |
3/526 |
|
pancreatic adenocarcinoma |
2/326 |
|
thyroid carcinoma |
1/426 |
|
Identification of ovarian granulosa cell tumours and Sertoli cell tumours:
differentiation from carcinomas (especially endometrioid carcinoma with a sex cord-like pattern)
differentiation of sarcomatoid growth pattern from soft tissue tumours
in combination with CD10, the differentiation from ovarian endometrial stromal tumour.
Differentiation of sex cord stromal tumours from reactive mesothlium in peritoneal washings, a situation in which calretinin is unhelpful6.
Possibly in the identification of choriocarcinoma25
Possibly in the identification of syncytiotrophoblast in testicular tumours25
References
This page last revised 20.3.2003.
©SMUHT/PW Bishop